UNLABELLED In order to determine whether auto antibodies were restricted to some subtypes of epilepsy, we included 81 unselected epileptic patients and 81 controls, studied clinical data, EEG, neuroimaging, measured antinuclear (ANA), anticardiolipin (aCL) and beta2GP1 antibodies. RESULTS Epilepsy was active in 74 patients, generalised in 78 and partial in 9. Auto antibodies were positive at ...

ANA is a project that examines legacy-free future networking architectures, with a focus on autonomicity. The programming model used in ANA dispenses with the rigid layers of the OSI model and instead uses bricks that can be combined to build a compartment offering the functionality required by an application. Restrictions such as TCP always being layered on top of IP do not exist, with e.g., a...

Fifty patients whose sera contained a speckled antinuclear antibody (ANA) were interviewed and examined to determine if there was any relationship between their clinical manifestations and the presence of certain serological markers. The results suggest that speckled ANA is usually found in patients with definite connective tissue diseases, but a significant minority have incomplete or early st...

Antinuclear antibodies (ANAs) are venerable biomarkers for assessing the diagnosis and prognosis of patients with autoimmunity. While closely associated with diseases such as systemic lupus erythematosus, ANA expression occurs commonly in healthy people. The basis for this expression is unknown, although it may reflect features of the assays for antibody detection or intrinsic immunological dis...

We report four female patients with Graves' disease with positive ANA antibodies and possibility for development of systemic lupus erythematosus. All four patients have been treated with antithyroid drugs. SLE symptoms have appeared from 4 to 12 months after the beginning of therapy with methysol in two of them. The third patient had no symptoms for SLE, but her ANA, anti-DNA, and antihistone a...

Hepatitis C VIruS (HCY) infection is characterized by a broad spectrum of clinical outcomes. An estimated 14%-46% of individuals exposed to HCY are able to clear the virus, while the other portion develops chronic (persistent) infections. Among the individuals with chronic HCY who are treated with interferon-based therapies, only a portion are able experience sustained virological suppression. ...